

Trastuzumab for injection

(r-DNA origin)

For I.V. Infusion, single-use vial
(Lyophilised powder)



Ogivri

(trastuzumab)

150 mg

1 vial of trastuzumab

 **Mylan**

Composition: Each vial contains: Trastuzumab (r-DNA origin) 150 mg, L-Histidine 2.16 mg, L-Histidine Hydrochloride 3.36 mg, Polyethylene Glycol 3350 (Macrogol 3350) 33.6 mg, D-Sorbitol 115.2 mg.

Storage: Store at temperature between 2°C to 8°C. Reconstitute with 7.2 mL Sterile Water for Injection USP (not supplied in this pack). Do not freeze the reconstituted solution. Use the solution immediately after reconstitution with SWFI, as it contains no preservatives. If not used immediately, store the reconstituted solution for up to 24 hours at 2°C to 8°C (36°F to 46°F); discard any unused solution after 24 hours.

Keep out of reach of children.

Do not use in case any foreign particulate matter is observed inside the vial after reconstitution.

Do not accept if seal is broken.

Dosage and Administration:

Read enclosed prescribing information sheet before use.

Manufactured by: M/s. Biocon Limited, Bengaluru, India

Manufactured for: Mylan Pharmaceuticals Private Limited, Plot No.1-A/2, MIDC industrial estate, Talaja, Panvel, Dist. Raigad – 410208, Maharashtra, India

Mfg Lic No.: KTK/28D/7/2006

BF000000

Imported by: Meda Pharma (Thailand) Co., Ltd., (A Mylan company), Bangkok, Thailand

Reg No. 1C 15027/61 (NBS)

คำเตือนความปลอดภัยกระทรวงสาธารณสุข
ยานี้อาจทำให้เกิดอันตรายหากใช้ไม่ถูกต้อง
ต้องให้แพทย์เฝ้าระวังการควบคุมของแพทย์เท่านั้น



ยาควบคุมพิเศษ

ใช้เฉพาะโรงพยาบาล

Batch No:

Mfg Date:

Exp. Date:

ยาสิ้นอายุ